Europe Unveils New Health Commissioner And Restructuring For Growth
This article was originally published in The Pink Sheet Daily
The EU’s new Health Commission Vytenis Andriukaitis will need to focus on growth and competitiveness, as the new Commission redistributes responsibility for pharmaceuticals.
You may also be interested in...
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.
Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.